Efficacy and Safety of MitraClip in the Treatment of Mitral Regurgitation: Comparison with Traditional Techniques

• DOI: https://doi.org/10.22533/at.ed.15953225221015

• Palavras-chave: MitraClip. Mitral Valve Insufficiency. Treatment. Morbidity MitraClip. Mitral Valve Insufficiency. Treatment. Morbidity

• Keywords: MitraClip. Mitral Valve Insufficiency. Treatment. Morbidity MitraClip. Mitral Valve Insufficiency. Treatment. Morbidity

• Abstract:

  Introduction: Secondary mitral regurgitation (MR) is a negative prognostic factor, affecting approximately 6.4% of the population aged 65 years or older. It results from dysfunction in mitral structures and can be classified as primary or secondary, guiding treatment options. MitraClip is a promising transcutaneous device approved for the treatment of MI, which reduces mitral regurgitation in patients at high surgical risk. Objective:  To compare the clinical outcomes and morbidity associated with the use of MitraClip compared to other traditional treatment techniques for MI. Method: A descriptive-analytical review of the literature was performed using the PUBMED Central database, focusing on articles published in the last five years on clinical outcomes and morbidity associated with MitraClip. Results: The initial search identified 72 articles, of which 23 were preselected for full-text reading and 16 were included in the final analysis. Discussion: MitraClip has been shown to be effective in reducing mitral regurgitation and improving patient symptoms, with lower mortality and rehospitalization rates compared to drug therapy alone. Although less invasive, it presents risks, such as structural complications. Conclusion: MitraClip represents a safe and effective alternative for high-risk patients with MI, comparable to conventional surgery. However, further studies are needed to validate its long-term efficacy in low- and intermediate-risk patients.